Get the Stockscreener App
36.93
0.41%
0.15
After Hours:
37.19
0.26
+0.70%
Cg Oncology Inc stock is traded at $36.93, with a volume of 288.26K.
It is up +0.41% in the last 24 hours and up +0.82% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$36.78
Open:
$36.75
24h Volume:
288.26K
Relative Volume:
0.47
Market Cap:
$2.41B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-69.06M
1W Performance:
+2.04%
1M Performance:
+0.82%
6M Performance:
+1.82%
1Y Performance:
+0.00%
1-Day Range:
$35.68
$37.04
1-Week Range:
$35.12
$37.09
52-Week Range:
$25.77
$50.23
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
Cg Oncology Inc Stock (CGON) Latest News
Vanguard Group Inc's Strategic Acquisition of CG Oncology Inc Sh - GuruFocus.com
CG Oncology To Report Final Results From CORE-001 Bladder Cancer Study Next Month - RTTNews
CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in October - MarketBeat
UBS Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN
CG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS Group - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oncolytic Virus Market Size is Set for Rapid Growth as Innovative - openPR
17,595 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by SG Americas Securities LLC - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
CG Oncology (NASDAQ:CGON) Earns "Buy" Rating from Bank of America - MarketBeat
The Potential Rise in the Price of Cg Oncology Inc. (CGON) following insiders activity - Knox Daily
Get in on Cg Oncology Inc.’s (CGON) buy-in window today! - SETE News
Renaissance Technologies LLC Grows Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Marshall Wace LLP Acquires New Shares in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth - Simply Wall St
Multiple players rev their Engenes in bladder cancer - BioWorld Online
Point72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Want To Improve Study Startup? Get More Efficient - Clinical Leader
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth - Yahoo Finance
How does Cg Oncology Inc. (CGON) change from a tortoise to a hare? - SETE News
RBC Capital Mkts initates Cg Oncology Inc. (CGON) stock to an Outperform - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLC - MarketBeat
Ensign Peak Advisors Inc Buys New Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market - Investing.com
Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market By Investing.com - Investing.com South Africa
Goldman Sachs maintains $52 target on CG Oncology shares By Investing.com - Investing.com Canada
Deerfield Management Company L.P. Series C Increases Stake in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Deerfield Management Company L.P. Series C Boosts Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
There is no way Cg Oncology Inc. (CGON) can keep these numbers up - SETE News
CGON: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Deeper Dive: Understanding Cg Oncology Inc. (CGON) Through its Various Ratios - The Dwinnex
Cg Oncology Inc. [CGON] Stock sold by Insider Song Hong Fang for $23.0 million - Knox Daily
RBC Capital Initiates Coverage of CG Oncology (CGON) with Outperform Recommendation - MSN
Yu Fan Makes New $49.83 Million Investment in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology (NASDAQ:CGON) Shares Gap Up to $39.00 - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Royal Bank of Canada - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Rhumbline Advisers - Defense World
Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) PT at $64.17 - MarketBeat
Selling Buzz: Cg Oncology Inc. [CGON] Director Song Hong Fang sells 650,455 shares of the company - Knox Daily
Wilson Sonsini Advises GC Therapeutics on $65 Million Series A - Wilson Sonsini
Waterloo Capital L.P. Purchases 1,517 Shares of Copart, Inc. (NASDAQ:CPRT) - Defense World
Corning’s stock rises as it sticks to Q3 profit view - MarketWatch
Compugen Ltd. (NASDAQ:CGEN) Short Interest Update - Defense World
CGN Resources Ltd. Options Cease Amid Unmet Conditions - TipRanks
Cognyte Software (NASDAQ:CGNT) Lifted to “Strong-Buy” at StockNews.com - Defense World
Canadian General Investments (TSE:CGI) Share Price Passes Above 50 Day Moving Average of $38.48 - MarketBeat
Why is the Cochlear share price in the red today? - The Motley Fool Australia
Calamos Global Total Return Fund (NASDAQ:CGO) Short Interest Update - Defense World
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.1% - Defense World
Adversity is less terrifying than hope: Cg Oncology Inc. (CGON) - SETE News
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):